Whether Acalabrutinib has been successfully included in medical insurance and what are the specific circumstances?

Acalabrutinib (Acalabrutinib) is a new generation BTK inhibitor that quickly attracted attention after being launched in China, mainly because of its mechanism of action and clinical application value for lymphoid system tumors. With the advancement of national medical insurance negotiations, acotinib has been officially included in the medical insurance catalog, significantly lowering the threshold for its use. In the past, the price of targeted drugs was generally high, and the original acotinib capsules (100mg*8 capsules*7 plates) could cost around 20,000 yuan before reimbursement, putting many patients under greater financial pressure in treatment decisions. After being covered by medical insurance, the out-of-pocket ratio will be divided by each province according to policies. The overall burden has dropped significantly compared with the initial stage of the launch, and it has also allowed more lymphoma patients to receive standardized treatment in regular hospitals.

The current medical insurance directory has a clear scope of application for acotinib. It mainly includes two categories of adult patients: one is chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least one kind of treatment in the past; the other is adult mantle cell lymphoma (MCL) who has been treated in the past. These diseases are characterized by abnormal lymphocyte proliferation, repeated relapses, and reduced sensitivity to traditional treatments, so the emergence of BTK inhibitors provides patients with a stable and more sustainable treatment modality.

After acotinib is included in medical insurance, patients usually need to get a prescription from a doctor in the hematology department of a tertiary hospital during the medical treatment process, and provide relevant diagnostic evidence, such as pathology reports, genetic testing or previous treatment records. After meeting the conditions, you can directly purchase medicines at the hospital pharmacy according to the medical insurance payment ratio. Since acotinib is a long-term drug, medical insurance reimbursement not only reduces the cost of a single box, but also significantly reduces the annual treatment cost, providing practical help for mid- and long-term management.

It should be noted that the reimbursement ratio, deductible and cap line vary in different regions. Patients can consult the local medical insurance department for specific amounts. Medical insurance coverage also means that the drug supply chain is more stable and avoids the risk of patients purchasing drugs through informal channels.

Reference materials:https://www.calquence.com/